Clinical Trial Update: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for MK-3475-03A, a Phase 1/2 study of immune and targeted therapy combinations in first-line renal cell carcinoma, sponsored by Merck; sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING